2005 Volume 56 Issue 4 Pages 336-342
We evaluated the efficacy and safety of a new combination chemotherapy including Docetaxel (TXT) and Nedaplatin (CDGP) as a second-line treatment for the advanced or recurrent esophageal carcinomas. Subsequent to administration of TXT at a dose of 60 mg for 60 minutes, CDGP was administered intravenously at a dose of 80 mg for 60 minutes. A total of nine male and one female with a median age of 65 (range 56-70) years were included and had been treated with prior chemotherapy. Prior treatments consisted of surgery and adjuvant chemoradiotherapy in 4 patients, surgery and adjuvant chemotherapy in 1 patient, chemotherapy for recurrent lesion after surgery in 3 patients, and chemotherapy alone in 2 patients. Eight patients underwent one course of treatment, 1 had two and 1 had three courses. Two PRs, 6 SDs and 2 NCs were obtained in all patients and the overall response rate was 20%. Median survival time was 170 days and median response time was 135 days. The prevailing toxicity was myelo-suppression with Grade 3 and 4 neutropenia occurring in 5 and 2 patients, respectively. The findings of this study indicated that a combination chemotherapy of TXT and CDGP is effective as a second-line treatment for advanced or recurrent esophageal cancers ; however, further investigations are needed to establish its efficacy.
